Business
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO, May 14, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones.
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/a8e9fee65fe67b489f6170e7d9a7ba68"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/j1msdF3HuMnvSVHGUW2A2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8e9fee65fe67b489f6170e7d9a7ba68","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/j45xGIq_VJBb8umk.zg71w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a8e9fee65fe67b489f6170e7d9a7ba68","width":1200,"height":424}},"lazy":false},{"type":"text","content":"- Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"- PIPE-791 chronic toxicity studies completed to support future Phase 2 trials","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"- Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) anticipated in the second half of 2025","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"- Cash runway projected through 2027","length":36,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, May 14, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones.","length":389,"tagName":"p"},{"type":"text","content":""We remain on track to achieve all of our clinical operations milestones and significant clinical data readouts," said Carmine Stengone, CEO, Contineum Therapeutics. "We expect to report topline data from our PIPE-791 Phase 1b positron emission tomography (PET) trial in the second quarter of 2025 and from our PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the second half of 2025."","length":455,"tagName":"p"},{"type":"text","content":"Stengone co...